Imatigen 100 Tablet contains Imatinib mesylate 100 mg, a selective tyrosine kinase inhibitor used primarily in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other malignancies characterized by specific genetic mutations. Imatinib mesylate acts by inhibiting the BCR-ABL tyrosine kinase enzyme, which is produced by the Philadelphia chromosome abnormality in CML, thereby preventing the proliferation of malignant cells. It also targets other tyrosine kinases such as c-KIT and PDGF receptors involved in tumor growth. Imatigen 100 is indicated for adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive CML, as well as those resistant or intolerant to prior therapies. The medication is administered orally, with dosage individualized based on the patient’s condition, response, and tolerability. Common adverse effects include edema, nausea, muscle cramps, rash, and fatigue, while serious side effects may involve myelosuppression, hepatotoxicity, and cardiotoxicity, necessitating regular monitoring of blood counts, liver function, and cardiac status during therapy. Imatigen 100 should be used under strict medical supervision, with adherence to prescribed dosing and monitoring protocols to optimize therapeutic outcomes and minimize risks.